Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Total Liabilities: 2015-2025

Historic Total Liabilities for Spyre Therapeutics (SYRE) over the last 10 years, with Sep 2025 value amounting to $49.5 million.

  • Spyre Therapeutics' Total Liabilities fell 47.17% to $49.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.5 million, marking a year-over-year decrease of 47.17%. This contributed to the annual value of $90.7 million for FY2024, which is 23.73% up from last year.
  • Spyre Therapeutics' Total Liabilities amounted to $49.5 million in Q3 2025, which was down 40.40% from $83.1 million recorded in Q2 2025.
  • Spyre Therapeutics' Total Liabilities' 5-year high stood at $253.6 million during Q2 2023, with a 5-year trough of $18.8 million in Q1 2023.
  • Its 3-year average for Total Liabilities is $87.2 million, with a median of $81.9 million in 2024.
  • Its Total Liabilities has fluctuated over the past 5 years, first soared by 1,024.50% in 2023, then tumbled by 75.68% in 2024.
  • Over the past 5 years, Spyre Therapeutics' Total Liabilities (Quarterly) stood at $26.0 million in 2021, then fell by 19.80% to $20.8 million in 2022, then surged by 251.69% to $73.3 million in 2023, then increased by 23.73% to $90.7 million in 2024, then crashed by 47.17% to $49.5 million in 2025.
  • Its last three reported values are $49.5 million in Q3 2025, $83.1 million for Q2 2025, and $87.2 million during Q1 2025.